These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 33612198)

  • 21. Comparative prices of diverted buprenorphine/naloxone and buprenorphine in a UK prison setting: a cross-sectional survey of drug using prisoners.
    Wright NM; Mohammed Z; Hughes GJ
    Drug Alcohol Depend; 2014 Nov; 144():254-8. PubMed ID: 25305714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mental health, chronic and infectious conditions among pregnant persons in US state prisons and local jails 2016-2017.
    Hendricks CA; Rajagopal KM; Sufrin CB; Kramer C; Jiménez MC
    Womens Health (Lond); 2024; 20():17455057241228748. PubMed ID: 38468474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons: A Systematic Review.
    Seval N; Wurcel A; Gunderson CG; Grimshaw A; Springer SA
    Infect Dis Clin North Am; 2020 Sep; 34(3):559-584. PubMed ID: 32782102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for heroin use following release from jail or prison in adults in a Central Appalachian state between 2012-2017.
    Smith KE; Archuleta A; Staton M; Winston E
    Am J Drug Alcohol Abuse; 2020; 46(4):485-497. PubMed ID: 33223579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
    Riggins DP; Cunningham CO; Ning Y; Fox AD
    Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
    Blue TR; Gordon MS; Schwartz RP; Couvillion K; Vocci FJ; Fitzgerald TT; O'Grady KE
    Addict Sci Clin Pract; 2019 Dec; 14(1):45. PubMed ID: 31787108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    Akiyama MJ; Ross J; Rimawi F; Fox A; Jordan AO; Wiersema J; Litwin AH; Kaba F; MacDonald R
    PLoS One; 2020; 15(12):e0242623. PubMed ID: 33264311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of interventions for older adults living in jails and prisons.
    Canada KE; Barrenger SL; Robinson EL; Washington KT; Mills T
    Aging Ment Health; 2020 Jul; 24(7):1019-1027. PubMed ID: 30869992
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacotherapy for opioid addiction in community corrections.
    Schwartz RP; Mitchell MM; O'Grady KE; Kelly SM; Gryczynski J; Mitchell SG; Gordon MS; Jaffe JH
    Int Rev Psychiatry; 2018 Oct; 30(5):117-135. PubMed ID: 30522370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Opportunities to Improve the Health of People Involved in the Criminal Justice System in the United States.
    Freudenberg N; Heller D
    Annu Rev Public Health; 2016; 37():313-33. PubMed ID: 26789388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
    Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
    J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
    Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
    J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.
    Friedmann PD; Hoskinson R; Gordon M; Schwartz R; Kinlock T; Knight K; Flynn PM; Welsh WN; Stein LA; Sacks S; O'Connell DJ; Knudsen HK; Shafer MS; Hall E; Frisman LK;
    Subst Abus; 2012; 33(1):9-18. PubMed ID: 22263709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007-14: a retrospective observational cohort study.
    Loeliger KB; Altice FL; Ciarleglio MM; Rich KM; Chandra DK; Gallagher C; Desai MM; Meyer JP
    Lancet HIV; 2018 Nov; 5(11):e617-e628. PubMed ID: 30197101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding interactions of formerly incarcerated HIV-positive men and transgender women with substance use treatment, medical, and criminal justice systems.
    Harawa NT; Amani B; Rohde Bowers J; Sayles JN; Cunningham W
    Int J Drug Policy; 2017 Oct; 48():63-71. PubMed ID: 28804052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film.
    White N; Ali R; Larance B; Zador D; Mattick RP; Degenhardt L
    Drug Alcohol Rev; 2016 Jan; 35(1):76-82. PubMed ID: 26331899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.